-
US starts Section 301 probe of Germany over pharmaceuticals
*US STARTS SECTION 301 PROBE OF GERMANY OVER PHARMACEUTICALS
— diego bloomberg (@diegobloomberg) June 19, 2026
Added at 7:32pm
-
USTR Announces Initiation of Section 301 Investigation of Germany’s Persistent Underpayment for Innovative Pharmaceutical Products
Today, U.S. Trade Representative Jamieson Greer initiated an investigation under Section 301 of the Trade Act of 1974 against Germany. This investigation will seek to determine whether persistent underpayment for innovative pharmaceutical products by Germany is unreasonable or discriminatory and burdens or restricts U.S. commerce. This investigation follows months of meaningful discussions with our German partners in an effort to resolve this issue. “President Trump has made clear that American patients should not be shouldering a disproportionate share of global pharmaceutical research and development,” said ... (full story)